CN105531380B - 应答羧胺三唑乳清酸盐的方法和多个信号转导通路的分子药效学生物标志物 - Google Patents

应答羧胺三唑乳清酸盐的方法和多个信号转导通路的分子药效学生物标志物 Download PDF

Info

Publication number
CN105531380B
CN105531380B CN201480050189.3A CN201480050189A CN105531380B CN 105531380 B CN105531380 B CN 105531380B CN 201480050189 A CN201480050189 A CN 201480050189A CN 105531380 B CN105531380 B CN 105531380B
Authority
CN
China
Prior art keywords
response
cto
pharmacodynamic
exposure
signaling pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480050189.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105531380A (zh
Inventor
拉希达·A·卡马利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of CN105531380A publication Critical patent/CN105531380A/zh
Application granted granted Critical
Publication of CN105531380B publication Critical patent/CN105531380B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201480050189.3A 2013-08-02 2014-07-30 应答羧胺三唑乳清酸盐的方法和多个信号转导通路的分子药效学生物标志物 Active CN105531380B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
CN105531380A CN105531380A (zh) 2016-04-27
CN105531380B true CN105531380B (zh) 2021-07-13

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480050189.3A Active CN105531380B (zh) 2013-08-02 2014-07-30 应答羧胺三唑乳清酸盐的方法和多个信号转导通路的分子药效学生物标志物

Country Status (9)

Country Link
US (1) US10378059B2 (enExample)
EP (1) EP3027776B1 (enExample)
JP (1) JP6913459B2 (enExample)
KR (1) KR102389934B1 (enExample)
CN (1) CN105531380B (enExample)
AU (1) AU2014296212B2 (enExample)
CA (1) CA2919690C (enExample)
IL (1) IL243894B (enExample)
WO (1) WO2015017545A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227205C (en) * 1995-07-21 2007-05-01 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
SI1504126T1 (sl) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
AU2008232732A1 (en) 2007-03-28 2008-10-09 Medarex, Inc. Methods of gene amplification and expression
JP2011515088A (ja) * 2008-03-22 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 増殖因子シグナル伝達経路レギュレーション状態を評価するための方法及び遺伝子発現サイン
KR101597338B1 (ko) * 2009-09-04 2016-02-24 탁티칼 떼라페우틱스 인크. 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
JP6355555B2 (ja) * 2011-04-01 2018-07-11 キアゲン Ｗｎｔ／ｂ−カテニンシグナル伝達経路に関する遺伝子発現シグネチャーおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Abstract 3350：Pluck hair as a biomarker platform for monitoring transcriptional consequences of clinical exposure to antagonism of the HDM2/P53 interaction in tumors;G Miele等;《Cancer Research》;20130415;第73卷;第3350页 *
Clinical pharmacogenomics：Applications in pharmaceutical R&D;M Norton等;《Drug Discovery Today》;20010101;第6卷(第4期);第180-185页 *

Also Published As

Publication number Publication date
KR20160030535A (ko) 2016-03-18
WO2015017545A1 (en) 2015-02-05
KR102389934B1 (ko) 2022-04-21
JP6913459B2 (ja) 2021-08-04
CN105531380A (zh) 2016-04-27
US20150038349A1 (en) 2015-02-05
US10378059B2 (en) 2019-08-13
AU2014296212A1 (en) 2016-02-25
EP3027776C0 (en) 2024-02-07
EP3027776B1 (en) 2024-02-07
IL243894B (en) 2020-06-30
CA2919690A1 (en) 2015-02-05
JP2016526908A (ja) 2016-09-08
IL243894A0 (en) 2016-04-21
AU2014296212B2 (en) 2020-10-22
CA2919690C (en) 2021-11-02
EP3027776A4 (en) 2017-03-08
HK1220493A1 (en) 2017-05-05
EP3027776A1 (en) 2016-06-08

Similar Documents

Publication Publication Date Title
Fuentes-Fayos et al. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3
Wilson et al. A functional landscape of resistance to ALK inhibition in lung cancer
Li et al. A pyroptosis-related gene signature for predicting survival in glioblastoma
Parashar et al. DNA methylation signatures of breast cancer in peripheral T-cells
Sheng et al. An integrated approach to biomarker discovery reveals gene signatures highly predictive of cancer progression
Gordian et al. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
Xu et al. Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy
Foy et al. The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer
Fiala et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
Chen et al. Identification and validation of an 11-ferroptosis related gene signature and its correlation with immune checkpoint molecules in glioma
He et al. Exploring PANoptosis in breast cancer based on scRNA-seq and bulk-seq
Ji et al. HTRA3 is a prognostic biomarker and associated with immune infiltrates in gastric cancer
Charlet et al. Genome‐wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma
López-Cortés et al. Identification of key proteins in the signaling crossroads between wound healing and cancer hallmark phenotypes
Bao et al. Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
Jiang et al. PRICKLE1, a Wnt/PCP signaling component, is overexpressed and associated with inferior prognosis in acute myeloid leukemia
Zhuang et al. PCSK9, a novel immune and ferroptosis related gene in abdominal aortic aneurysm neck
Grassi et al. The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia
CHEN et al. Biomarkers and transcriptome profiling of lung cancer
Johnson et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
CN105531380B (zh) 应答羧胺三唑乳清酸盐的方法和多个信号转导通路的分子药效学生物标志物
Erkin et al. Integrative analysis for identification of therapeutic targets and prognostic signatures in non-small cell lung cancer
Su et al. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma
Tange et al. MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway
Ma et al. Establishment and validation of an eight-gene metabolic–related prognostic signature model for lung adenocarcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant